VYXEOS
DESIGNED FOR OPTIMAL SYNERGISTIC ACTIVITY¹

*1:5 ratio is 1 part daunorubicin to 5 parts cytarabine.    

References: 1. Tolcher AW, Mayer LD. Improving combination cancer therapy: the CombiPlex^® development platform. Future Oncol 2018;14:1317–1332. 2. Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin Drug Deliv 2010;7:1329–41.